RYBELSUS Drug Patent Profile

« Back to Dashboard

When do Rybelsus patents expire, and when can generic versions of Rybelsus launch?

Rybelsus is a drug marketed by Novo and is included in one NDA. There are fifteen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in RYBELSUS is semaglutide. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Rybelsus

Rybelsus was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2033. This may change due to patent challenges or generic licensing.

There have been eighteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for RYBELSUS

US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	16
Patent Applications:	2,152
Drug Prices:	Drug price information for RYBELSUS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYBELSUS
What excipients (inactive ingredients) are in RYBELSUS?	RYBELSUS excipients list
DailyMed Link:	RYBELSUS at DailyMed

See drug prices for RYBELSUS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RYBELSUS

Constraining patent/regulatory exclusivity:

10,933,120

NDA:

213051

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RYBELSUS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	PHASE2
Herlev Hospital	PHASE2
Rune Skovgaard Rasmussen	PHASE2

See all RYBELSUS clinical trials

Pharmacology for RYBELSUS

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for RYBELSUS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYBELSUS	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	213051	1	2025-12-11
RYBELSUS	Tablets	semaglutide	3 mg, 7 mg and 14 mg	213051	1	2024-07-15

US Patents and Regulatory Information for RYBELSUS

RYBELSUS is protected by fifteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,933,120.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes	11,759,502		Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes	12,594,326		Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes	11,759,502		Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes	9,278,123		Y

Expired US Patents for RYBELSUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-001	Sep 20, 2019	8,536,122
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019	8,536,122
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019	8,536,122

EU/EMA Drug Approvals for RYBELSUS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for RYBELSUS

When does loss-of-exclusivity occur for RYBELSUS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYBELSUS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011343190
Brazil	112013014942
Canada	2821886
China	103260608
China	105963685

Supplementary Protection Certificates for RYBELSUS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	122018000075	Germany		PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208

Rybelsus Market Dynamics, Financial Trajectory, Patent Estate, and Generic Entry Risk

Last updated: October 3, 2026

Rybelsus, Novo Nordisk's oral semaglutide product, is a high-growth diabetes medicine positioned within the company's broader GLP-1 franchise. Its commercial value comes from oral administration, strong glycemic efficacy, and access to the same semaglutide platform used in Ozempic and Wegovy. Its principal constraints are supply allocation, competition from injectable GLP-1 and dual GIP/GLP-1 products, pricing pressure, and eventual generic exposure after key U.S. patents expire.

How large is the Rybelsus market?

Rybelsus is approved for adults with type 2 diabetes as an adjunct to diet and exercise. It is supplied in 3 mg, 7 mg, and 14 mg tablets, with 3 mg used as an initiation dose rather than a maintenance dose. The product uses semaglutide with SNAC, an absorption-enhancing excipient that enables oral delivery.

Novo Nordisk reported Rybelsus sales of approximately DKK 14.4 billion in 2023, up about 66% from 2022 at constant exchange rates. The product remained substantially smaller than Ozempic, which generated approximately DKK 95.7 billion in 2023, but Rybelsus expanded faster from a lower base. Novo's total 2023 sales were approximately DKK 232.3 billion. [1]

Metric	Rybelsus position
Active ingredient	Semaglutide
Administration	Once-daily oral tablet
U.S. approval	September 2019
U.S. indication	Type 2 diabetes
Maintenance strengths	7 mg and 14 mg
2023 Novo sales	Approximately DKK 14.4 billion
Primary manufacturer	Novo Nordisk
Key delivery technology	SNAC oral absorption enhancer
Main competitors	Ozempic, Mounjaro, Trulicity, Jardiance, oral GLP-1 candidates

Rybelsus benefits from patients who prefer tablets over injections and from physicians seeking a semaglutide product without initiating injectable therapy. Its use is also supported by the clinical performance of the broader semaglutide class.

What is driving Rybelsus revenue growth?

Rybelsus revenue growth has been driven by five factors:

1. Expansion of GLP-1 prescribing in type 2 diabetes.
2. Increased physician familiarity with semaglutide.
3. Oral administration for injection-averse patients.
4. Novo Nordisk's commercial infrastructure and payer relationships.
5. Cross-franchise demand generated by Ozempic and Wegovy.

The oral format does not eliminate titration or gastrointestinal tolerability issues. Patients generally begin at 3 mg, increase to 7 mg after 30 days, and may advance to 14 mg. Administration requirements, including taking the tablet on an empty stomach with a limited amount of water and waiting before eating, can reduce convenience relative to weekly injectables.

Rybelsus also competes with the perception that injectable semaglutide and tirzepatide deliver stronger weight-loss outcomes. Because Rybelsus is approved for diabetes rather than chronic weight management, its commercial positioning differs from Wegovy and Lilly's obesity portfolio.

How does Rybelsus compare with Ozempic, Wegovy, and Mounjaro?

Rybelsus is differentiated by oral delivery, while Ozempic and Wegovy use once-weekly subcutaneous injections. Mounjaro uses tirzepatide, a dual GIP/GLP-1 agonist.

Product	Company	Active ingredient	Route	Primary commercial use	Strategic position
Rybelsus	Novo Nordisk	Semaglutide	Oral daily	Type 2 diabetes	Tablet-based GLP-1 entry
Ozempic	Novo Nordisk	Semaglutide	Injectable weekly	Type 2 diabetes	Core diabetes franchise
Wegovy	Novo Nordisk	Semaglutide	Injectable weekly	Chronic weight management	Obesity franchise
Mounjaro	Eli Lilly	Tirzepatide	Injectable weekly	Type 2 diabetes	High-efficacy competitor
Trulicity	Eli Lilly	Dulaglutide	Injectable weekly	Type 2 diabetes	Established GLP-1 competitor
Jardiance	Boehringer Ingelheim/Eli Lilly	Empagliflozin	Oral daily	Type 2 diabetes	Oral non-GLP-1 alternative

Rybelsus has a route-of-administration advantage against injectable products, but Mounjaro and Ozempic compete directly for treatment decisions in patients who prioritize efficacy, weight loss, or dosing frequency.

Lilly's oral orforglipron program represents a potentially important future competitor because it is designed as a non-peptide oral GLP-1 receptor agonist. Its commercial impact depends on regulatory approval, clinical efficacy, tolerability, manufacturing scale, and pricing.

What patents protect Rybelsus?

Rybelsus is protected by several layers of intellectual property:

• Semaglutide compound patents.
• Pharmaceutical composition patents.
• Oral delivery and absorption-enhancement patents.
• Dosage and administration patents.
• Method-of-use patents.
• Manufacturing and formulation know-how involving semaglutide and SNAC.

Key U.S. patent families associated with semaglutide and Rybelsus include U.S. Patent No. 8,129,343 and later patents directed to compositions and uses. The compound patent has been identified in public regulatory and patent records with an expiration date in 2026, subject to patent-term adjustment and applicable regulatory extensions. Later formulation and use patents extend protection into the early-to-mid 2030s. [2][3]

Protection category	Commercial purpose	Expected risk period
Semaglutide compound protection	Protects the active molecule	Earliest major expiry in the mid-2020s
Oral composition protection	Protects semaglutide with absorption enhancer	Extends protection beyond compound expiry
Dosing and treatment patents	Protects selected regimens and uses	Relevant to Paragraph IV litigation
Manufacturing rights and know-how	Protects peptide production and tablet performance	Can delay practical competition

The value of the later patents depends on claim scope, validity, infringement exposure, and whether an ANDA applicant can design around the protected formulation or use.

When does Rybelsus lose exclusivity?

Rybelsus does not have a single effective loss-of-exclusivity date. The first semaglutide patent expirations create a potential entry point, while later formulation and method-of-use patents can delay or narrow generic entry.

The commercial timeline is:

Period	Exclusivity event
2019	FDA approval of Rybelsus
2024	Five-year new chemical entity exclusivity had expired
2026	Early compound-patent expiry window
2026-2031	Potential generic litigation and formulation-patent disputes
Early-to-mid 2030s	Later formulation and use-patent expiry windows

FDA five-year new chemical entity exclusivity for Rybelsus expired in 2024. That date did not authorize immediate generic launch because FDA approval exclusivity and patent protection operate separately. [4]

The earliest practical generic launch could occur before the final listed patent expiry if an applicant prevails in Paragraph IV litigation, reaches a settlement with Novo Nordisk, or launches at risk. A later launch is more likely if formulation patents survive challenge and cover commercially important tablet presentations.

What is the Orange Book status of Rybelsus?

Rybelsus is an FDA-approved small-molecule drug product listed in the Orange Book. Its listed patents cover the semaglutide product and related formulation or use claims. Orange Book listings provide the patent basis for ANDA applicants to make Paragraph IV certifications and for the reference-product sponsor to file patent litigation. [4]

Rybelsus is not a biologic for purposes of the FDA biosimilar pathway. Semaglutide is a chemically manufactured peptide drug, and a competing product would generally pursue an abbreviated new drug application under section 505(j), subject to FDA requirements for sameness, bioequivalence, and applicable patent certifications.

Which companies are challenging Rybelsus patents?

Generic manufacturers have commercial incentives to challenge Rybelsus because semaglutide is one of the highest-value diabetes molecules in the market. Public patent records and litigation filings identify ANDA-related activity involving generic applicants, including Mylan-related entities.

Paragraph IV litigation generally creates a 30-month stay of final FDA approval when the reference sponsor files suit within the statutory period. The litigation issues are likely to include:

• Whether the asserted patents are invalid for obviousness or lack of enablement.
• Whether the generic tablet uses the claimed absorption-enhancing composition.
• Whether the proposed label induces infringement of method-of-use claims.
• Whether later-filed formulation patents are properly listed.
• Whether a generic applicant can omit protected indications through a section viii statement.

A successful challenge to the compound patent would not necessarily clear the formulation patents. Conversely, an applicant may avoid some method-of-use claims through label carve-outs while still facing composition claims.

What licensing deals support Rybelsus?

Rybelsus depends on SNAC, an absorption-enhancing technology originally associated with Emisphere Technologies. Novo Nordisk acquired Emisphere in 2020 for approximately $1.8 billion, obtaining rights to the Eligen oral delivery technology and related intellectual property. [5]

The transaction reduced Novo's dependence on a third-party technology supplier and consolidated control over the oral semaglutide platform. It also strengthened Novo's ability to manage future oral GLP-1 products, manufacturing scale-up, and patent enforcement.

How strong is the Rybelsus patent estate?

The Rybelsus patent estate is commercially strong but more complex than a single compound patent.

Its strengths are:

• Semaglutide has broad clinical and commercial validation.
• Oral delivery requires a specific absorption-enhancement system.
• The product combines active ingredient, excipient, dose, and administration conditions.
• Novo owns or controls the key oral-delivery technology after the Emisphere acquisition.
• Later formulation patents may create a second barrier after compound expiry.

Its vulnerabilities are:

• Compound protection reaches its earliest expiry window in the mid-2020s.
• Generic applicants can attack multiple patents in coordinated Paragraph IV filings.
• Method-of-use claims can sometimes be bypassed through label carving.
• Formulation claims may face obviousness and enablement challenges.
• A generic tablet may not need to replicate every commercial feature of Rybelsus.

The estate is stronger against simple copying than against a carefully designed non-infringing formulation. Novo's litigation position will depend on the claims asserted, the applicant's proposed formulation, and the timing of FDA approval.

What generic entry risks exist for Rybelsus?

The principal generic-entry scenarios are:

Early settlement entry

Novo could settle with one or more generic applicants and provide a licensed entry date before the last patent expires. The settlement could include supply, launch sequencing, or restrictions tied to particular strengths.

Court victory for a generic applicant

A final invalidity or non-infringement ruling could permit launch before later patent expirations. Such a result could reset the value of the entire oral semaglutide franchise.

At-risk launch

A generic company could launch before final resolution, accepting potential damages or an injunction risk. This is less likely where the branded product has high sales and the patent estate includes multiple formulation claims.

Staggered entry by dosage form

Generic applicants could enter with selected strengths or a formulation that avoids particular claims. This would create partial rather than complete erosion.

The economic impact depends on whether generic competition reaches the 7 mg and 14 mg maintenance doses, which generate the core chronic-treatment volume.

What manufacturing and supply barriers protect Rybelsus?

Rybelsus has meaningful manufacturing barriers even apart from patents. Production requires:

• Pharmaceutical-grade semaglutide peptide.
• Controlled coupling and purification processes.
• Consistent tablet content uniformity.
• Reliable SNAC formulation performance.
• Stability through packaging and distribution.
• Large-scale quality-control capacity.

Novo has invested heavily in expanding GLP-1 manufacturing capacity. Supply constraints have historically affected the broader semaglutide franchise, especially injectable products. Rybelsus can benefit from manufacturing prioritization, but it also competes internally with Ozempic and Wegovy for active pharmaceutical ingredient and production resources.

Manufacturing barriers can delay generic scale-up but generally do not provide the same durable protection as enforceable patents.

What is the FDA regulatory status of Rybelsus?

The FDA approved Rybelsus in September 2019 for adults with type 2 diabetes. The product is administered once daily and is used with diet and exercise. It is not FDA-approved as a chronic weight-management product. [6]

The product's label, safety profile, titration schedule, and administration instructions create commercial differentiation but also limit substitution with injectable obesity products. FDA approval of future higher-dose oral semaglutide products could expand the platform, but such products would require separate regulatory action and would not automatically receive the same indication as Rybelsus.

How will Rybelsus affect Novo Nordisk's financial trajectory?

Rybelsus should remain a material contributor to Novo's diabetes revenue, but its growth rate will likely moderate as the product matures and the broader GLP-1 market becomes more competitive.

The financial trajectory has three phases:

1. Early adoption: rapid growth from an oral alternative to injectable GLP-1 therapy.
2. Franchise expansion: increased use as semaglutide awareness and payer access improve.
3. Maturity and erosion: slower growth as tirzepatide, oral competitors, and generic challenges intensify.

Rybelsus is strategically valuable even though Ozempic and Wegovy generate more revenue. It gives Novo an oral entry point, supports patient conversion within the semaglutide franchise, and provides a platform for future oral GLP-1 development.

The major financial risks are price concessions, payer utilization management, supply allocation, adverse safety developments, competing oral therapies, and patent litigation. The principal upside is continued expansion of GLP-1 treatment among patients who prefer a tablet or cannot sustain injectable therapy.

Key Takeaways

• Rybelsus generated approximately DKK 14.4 billion in Novo Nordisk sales in 2023.
• Its principal commercial advantage is once-daily oral semaglutide.
• Ozempic, Wegovy, Mounjaro, and future oral GLP-1 products create substantial competitive pressure.
• Compound protection begins to weaken in the mid-2020s, while formulation and use patents extend protection into the early-to-mid 2030s.
• Rybelsus is an FDA-listed small-molecule drug, not a biosimilar product.
• Generic entry will depend on Paragraph IV litigation, formulation design, patent settlements, and FDA approval timing.
• The Emisphere acquisition gave Novo greater control over SNAC and oral-delivery technology.
• Rybelsus is likely to remain a significant product, but its growth rate should decelerate as the franchise matures.

FAQs About Rybelsus Patents, Sales, and Generic Competition

Is Rybelsus more valuable than Ozempic to Novo Nordisk?

No. Ozempic generates substantially higher revenue. Rybelsus is strategically important because it provides an oral semaglutide option and expands the addressable diabetes market.

Can a generic company copy Rybelsus after the semaglutide compound patent expires?

Not necessarily. A generic applicant must also address listed formulation, composition, and method-of-use patents. It may need to avoid or invalidate those patents before launch.

Does Rybelsus have biosimilar competition?

No. Rybelsus is regulated as a chemically manufactured drug product. Competitive products would generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

Why did Novo Nordisk acquire Emisphere?

Novo acquired Emisphere to control SNAC-based oral delivery technology and reduce dependence on an external supplier for Rybelsus and future oral peptide products.

Is Rybelsus approved for weight loss?

No. Rybelsus is approved for type 2 diabetes. Wegovy is Novo Nordisk's semaglutide product approved for chronic weight management.

References

1. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.
2. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,129,343. U.S. Department of Commerce.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Rybelsus. FDA.
4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
5. Novo Nordisk A/S. (2020, September 1). Novo Nordisk to acquire Emisphere Technologies. Novo Nordisk.
6. U.S. Food and Drug Administration. (2019, September 20). FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA.